ABMD - Replacement Heart System Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABMD - Replacement Heart System

ABMD 381.02

0.0%

Jan 3 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BostonView who wrote (12)	12/9/1999 10:54:00 PM
From: Mindshare	Read Replies (2) of 147

There are three possibilities fueling this run: 1. Momentum trading pushing the stock way higher than it should be based on human trial anticipation. Revenue from Abiocor is 3 years away minimum and this assumes the device is safe and effective in humans. 2. Buyout by a larger medical company. This is supposedly what started the run two months ago. However, there is no indication this is going to happen. BVS sales were down this quarter and have been pretty much flat recently. Abiocor is a wild card. It could generate billions or nothing. Genzyme owns 17% of the company, but I doubt they would want the rest of it. 3. Acquisition or development of new promising technology. The company is usually very quiet and conservative considering they are the last great shot at a TAH. They would probably be just as quiet about something that would change the mission statement of the company. However, insiders or analysts would know if something was brewing and begin buying the stock. I personally feel No. 1 is the most plausible, but would not be surprised if No. 3 were true. No. 2 is rumor and the least likely IMHO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next